US 11,890,356 B2
HDAC6 inhibitors and imaging agents
Jacob Hooker, Belmont, MA (US); Changning Wang, Melrose, MA (US); Martin Georg Strebl-Bantillo, Somerville, MA (US); and Johanna Kaarina Rokka, Boston, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Filed by The General Hospital Corporation, Boston, MA (US)
Filed on Nov. 16, 2021, as Appl. No. 17/455,170.
Application 17/455,170 is a continuation of application No. 16/603,746, granted, now 11,207,431, previously published as PCT/US2018/027077, filed on Apr. 11, 2018.
Claims priority of provisional application 62/484,207, filed on Apr. 11, 2017.
Prior Publication US 2022/0133916 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/04 (2006.01); C07C 259/10 (2006.01)
CPC A61K 51/04 (2013.01) [C07C 259/10 (2013.01); C07B 2200/05 (2013.01); C07C 2602/42 (2017.05); C07C 2603/74 (2017.05)] 17 Claims
 
1. A composition comprising a radiolabeled compound of the formula

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.